Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Gilead Sciences
(NQ:
GILD
)
89.51
+0.69 (+0.78%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Nov 1, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Gilead Sciences
< Previous
1
2
...
12
13
14
15
16
17
18
19
20
...
51
52
Next >
Gilead's Breast Cancer Drug Shows Promise When Combined With Merck's Treatment
September 11, 2023
Gilead Sciences Inc (NASDAQ: GILD) revealed early data from its open-label, Phase 2 EVOKE-02 study evaluating Trodelvy.
Via
Benzinga
Gilead’s Phase 2 EVOKE-02 Study of Trodelvy® (sacituzumab govitecan-hziy) in Combination With KEYTRUDA® (pembrolizumab) Demonstrates Promising Clinical Activity in First-Line Metastatic Non-Small Cell Lung Cancer
September 10, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
What You Need to Know About Hepatitis C This Recovery Month
September 08, 2023
(BPT) - Hepatitis C (HCV) is often referred to as the 'silent disease' due to silent symptoms that may not appear until years after exposure. In fact, of the more than 2 million Americans who are...
Via
Brandpoint
Exposures
COVID-19
How To Earn $500 A Month From Gilead Sciences Stock
September 08, 2023
Shares of Gilead Sciences, Inc (NASDAQ: GILD) are trading higher during Friday’s trading session, bolstered by the Bank of America Securities bullish outlook on the stock.
Via
Benzinga
$1000 Invested In This Stock 20 Years Ago Would Be Worth $9,000 Today
September 07, 2023
Via
Benzinga
Where Gilead Sciences Stands With Analysts
September 06, 2023
Via
Benzinga
(GILD) - Analyzing Gilead Sciences's Short Interest
September 05, 2023
Via
Benzinga
Infectious Disease Player Vir Biotech Has Limited Near Term Upside, Analyst Downgrades
September 08, 2023
BofA Securities has downgraded Vir Biotechnology Inc (NASDAQ: VIR) to Neutral from Buy with a price target of $14,
Via
Benzinga
The Unexpected Reason Gilead Just Notched Its Biggest Single-Day Move In A Month
September 08, 2023
Gilead shares are on the rise amid an unexpected boon for its HIV treatment business.
Via
Investor's Business Daily
Gilead Sciences Shares Trade Higher After Bullish Analyst Upgrades Stock
September 08, 2023
Shares of Gilead Sciences, Inc. (NASDAQ: GILD) are trading higher into Friday’s trading session after Bank of America Securities upgraded the stock, highlighting an underappreciated growth potential in...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 8, 2023
September 08, 2023
Via
Benzinga
Adobe To Rally Over 12%? Here Are 10 Other Analyst Forecasts For Friday
September 08, 2023
B of A Securities cut the price target for DigitalOcean Holdings, Inc. (NYSE: DOCN) from $47 to $25. B of A Securities analyst Wamsi Mohan downgraded the stock from Buy to Underperform. DigitalOcean...
Via
Benzinga
Gilead Prices $2 Billion of Senior Unsecured Notes
September 07, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
3 No-Brainer Dividend Stocks to Buy in September
September 02, 2023
Income investors should really like these biopharma stocks with juicy dividends.
Via
The Motley Fool
Nearing Retirement? These Stocks Will Pay You For Life
August 29, 2023
These companies are passive income machines.
Via
The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
August 28, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 6, 2023
September 06, 2023
Via
Benzinga
GILD Stock Alert: FDA Approves Gilead Sciences’ Veklury Covid-19 Treatment
August 24, 2023
Gilead Sciences (GILD) stock is on the move Thursday following additional FDA approval for its Veklury Covid-19 treatment.
Via
InvestorPlace
Exposures
COVID-19
Product Safety
FDA Approves Veklury® (Remdesivir) to Treat COVID-19 in People With Mild to Severe Hepatic Impairment With no Dose Adjustment
August 24, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead Sciences to Present at Upcoming Investor Conferences
August 23, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Who Are Other Players Gaining From Roche's Accidental Lung Cancer Data Update
August 23, 2023
Earlier today, Roche Holdings AG (OTC: RHHBY) announced that it had been made aware of inadvertent disclosure of the second interim analysis of Phase 3 SKYSCRAPER-01 study, evaluating tiragolumab plus...
Via
Benzinga
How Roche's Accidental Cancer Update Lifted Iteos And Arcus More Than 30%
August 23, 2023
Roche provided an update from its study in lung cancer using an anti-TIGIT drug.
Via
Investor's Business Daily
San Francisco Business Times Names Landis Communications Inc. (Landis) the Top 2022 Bay Area Corporate Philanthropist as a Percentage Of Profits
August 22, 2023
--News Direct--
Via
News Direct
Topics
LGBTQ
Exposures
Diversity
Large Cap Biopharmaceuticals Performance 2023 YTD: Mixed Results But Lilly Is A Big Winner
August 21, 2023
Biotech stocks are in a bear market since the IBB hit $177.37 in 2021 and is down 7.84% over five years.
Via
Talk Markets
FDA Pauses Gilead's Investigational Magrolimab Study In Blood Cancer Patients
August 21, 2023
FDA has placed a partial clinical hold on Gilead Sciences Inc (NASDAQ: GILD) initiation of new patients in U.S.
Via
Benzinga
Exposures
Product Safety
5 Safe Stocks Under $40 to Buy Immediately
August 21, 2023
Investors are turning away from risky bets and putting their money in safe stocks this week. Here are four names under $40 to buy now.
Via
InvestorPlace
Gilead Announces Partial Clinical Hold for Magrolimab Studies in AML
August 21, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead Sciences and Meharry Medical College Highlight Five-Year Impact of Gilead COMPASS Initiative® on HIV in the Southern United States
August 18, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
10 Health Care Stocks With Whale Alerts In Today's Session
August 17, 2023
Via
Benzinga
Autolus Therapeutics' Obe-Cel's Shows Compelling Safety Over Gilead's Drug For Acute Lymphoblastic Leukemia
August 17, 2023
Truist has raised the price target for Autolus Therapeutics PLC (NASDAQ: AUTL) from $6 to $9
Via
Benzinga
< Previous
1
2
...
12
13
14
15
16
17
18
19
20
...
51
52
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.